164 related articles for article (PubMed ID: 24756820)
1. Targeting ribonucleotide reductase M2 subunit by small interfering RNA exerts anti-oncogenic effects in gastric adenocarcinoma.
Kang W; Tong JH; Chan AW; Zhao J; Wang S; Dong Y; Sin FM; Yeung S; Cheng AS; Yu J; To K
Oncol Rep; 2014 Jun; 31(6):2579-86. PubMed ID: 24756820
[TBL] [Abstract][Full Text] [Related]
2. Expression of ribonucleotide reductase M2 subunit in gastric cancer and effects of RRM2 inhibition in vitro.
Morikawa T; Hino R; Uozaki H; Maeda D; Ushiku T; Shinozaki A; Sakatani T; Fukayama M
Hum Pathol; 2010 Dec; 41(12):1742-8. PubMed ID: 20825972
[TBL] [Abstract][Full Text] [Related]
3. MCM7 serves as a prognostic marker in diffuse-type gastric adenocarcinoma and siRNA-mediated knockdown suppresses its oncogenic function.
Kang W; Tong JH; Chan AW; Cheng AS; Yu J; To K
Oncol Rep; 2014 May; 31(5):2071-8. PubMed ID: 24647462
[TBL] [Abstract][Full Text] [Related]
4. KRAS-mediated up-regulation of RRM2 expression is essential for the proliferation of colorectal cancer cell lines.
Yoshida Y; Tsunoda T; Doi K; Tanaka Y; Fujimoto T; Machida T; Ota T; Koyanagi M; Takashima Y; Sasazuki T; Kuroki M; Iwasaki A; Shirasawa S
Anticancer Res; 2011 Jul; 31(7):2535-9. PubMed ID: 21873171
[TBL] [Abstract][Full Text] [Related]
5. The prognostic value of ribonucleotide reductase small subunit M2 in predicting recurrence for prostate cancers.
Huang Y; Liu X; Wang YH; Yeh SD; Chen CL; Nelson RA; Chu P; Wilson T; Yen Y
Urol Oncol; 2014 Jan; 32(1):51.e9-19. PubMed ID: 24360663
[TBL] [Abstract][Full Text] [Related]
6. Potent siRNA inhibitors of ribonucleotide reductase subunit RRM2 reduce cell proliferation in vitro and in vivo.
Heidel JD; Liu JY; Yen Y; Zhou B; Heale BS; Rossi JJ; Bartlett DW; Davis ME
Clin Cancer Res; 2007 Apr; 13(7):2207-15. PubMed ID: 17404105
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of RRM2 in gastric cancer cell promotes their invasiveness via AKT/NF-κB signaling pathway.
Zhong Z; Cao Y; Yang S; Zhang S
Pharmazie; 2016 May; 71(5):280-4. PubMed ID: 27348973
[TBL] [Abstract][Full Text] [Related]
8. E2F1 promote the aggressiveness of human colorectal cancer by activating the ribonucleotide reductase small subunit M2.
Fang Z; Gong C; Liu H; Zhang X; Mei L; Song M; Qiu L; Luo S; Zhu Z; Zhang R; Gu H; Chen X
Biochem Biophys Res Commun; 2015 Aug; 464(2):407-15. PubMed ID: 26093293
[TBL] [Abstract][Full Text] [Related]
9. A Novel Mechanism Driving Poor-Prognosis Prostate Cancer: Overexpression of the DNA Repair Gene, Ribonucleotide Reductase Small Subunit M2 (RRM2).
Mazzu YZ; Armenia J; Chakraborty G; Yoshikawa Y; Coggins SA; Nandakumar S; Gerke TA; Pomerantz MM; Qiu X; Zhao H; Atiq M; Khan N; Komura K; Lee GM; Fine SW; Bell C; O'Connor E; Long HW; Freedman ML; Kim B; Kantoff PW
Clin Cancer Res; 2019 Jul; 25(14):4480-4492. PubMed ID: 30996073
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of hepatocellular carcinoma growth using immunoliposomes for co-delivery of adriamycin and ribonucleotide reductase M2 siRNA.
Gao J; Chen H; Yu Y; Song J; Song H; Su X; Li W; Tong X; Qian W; Wang H; Dai J; Guo Y
Biomaterials; 2013 Dec; 34(38):10084-98. PubMed ID: 24060417
[TBL] [Abstract][Full Text] [Related]
11. KITENIN is associated with tumor progression in human gastric cancer.
Ryu HS; Park YL; Park SJ; Lee JH; Cho SB; Lee WS; Chung IJ; Kim KK; Lee KH; Kweon SS; Joo YE
Anticancer Res; 2010 Sep; 30(9):3479-86. PubMed ID: 20944126
[TBL] [Abstract][Full Text] [Related]
12. RRM2 promotes the progression of human glioblastoma.
Li C; Zheng J; Chen S; Huang B; Li G; Feng Z; Wang J; Xu S
J Cell Physiol; 2018 Oct; 233(10):6759-6767. PubMed ID: 29667764
[TBL] [Abstract][Full Text] [Related]
13. Suppression of RRM2 inhibits cell proliferation, causes cell cycle arrest and promotes the apoptosis of human neuroblastoma cells and in human neuroblastoma RRM2 is suppressed following chemotherapy.
Li J; Pang J; Liu Y; Zhang J; Zhang C; Shen G; Song L
Oncol Rep; 2018 Jul; 40(1):355-360. PubMed ID: 29749541
[TBL] [Abstract][Full Text] [Related]
14. Ribonucleotide reductase M2 subunit expression and prognostic value in nasopharyngeal carcinoma.
Han P; Lin ZR; Xu LH; Zhong Q; Zhu XF; Liang FY; Cai Q; Huang XM; Zeng MS
Mol Med Rep; 2015 Jul; 12(1):401-9. PubMed ID: 25695839
[TBL] [Abstract][Full Text] [Related]
15. Knockdown of HMGB1 inhibits growth and invasion of gastric cancer cells through the NF-κB pathway in vitro and in vivo.
Zhang J; Kou YB; Zhu JS; Chen WX; Li S
Int J Oncol; 2014 Apr; 44(4):1268-76. PubMed ID: 24481712
[TBL] [Abstract][Full Text] [Related]
16. Small interfering RNA (siRNA)-mediated silencing of the M2 subunit of ribonucleotide reductase: a novel therapeutic strategy in ovarian cancer.
Zhang M; Wang J; Yao R; Wang L
Int J Gynecol Cancer; 2013 May; 23(4):659-66. PubMed ID: 23466567
[TBL] [Abstract][Full Text] [Related]
17. RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine.
Duxbury MS; Ito H; Zinner MJ; Ashley SW; Whang EE
Oncogene; 2004 Feb; 23(8):1539-48. PubMed ID: 14661056
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of CD24 inhibits invasive growth, facilitates apoptosis and enhances chemosensitivity in gastric cancer AGS cells.
Jiao XL; Zhao C; Niu M; Chen D
Eur Rev Med Pharmacol Sci; 2013 Jul; 17(13):1709-15. PubMed ID: 23852892
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of mRNA by Q-RTPCR and protein expression by AQUA of the M2 subunit of ribonucleotide reductase (RRM2) in human tumors.
Kolesar J; Huang W; Eickhoff J; Hahn K; Alberti D; Attia S; Schelman W; Holen K; Traynor A; Ivy P; Wilding G
Cancer Chemother Pharmacol; 2009 Jun; 64(1):79-86. PubMed ID: 18941749
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of catalytic subunit M2 in patients with ovarian cancer.
Wang LM; Lu FF; Zhang SY; Yao RY; Xing XM; Wei ZM
Chin Med J (Engl); 2012 Jun; 125(12):2151-6. PubMed ID: 22884145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
